Today: 21 May 2026
IonQ stock steadies after South Korea 100-qubit Tempo deal as traders eye $45 level
31 December 2025
2 mins read

IonQ stock steadies after South Korea 100-qubit Tempo deal as traders eye $45 level

NEW YORK, December 30, 2025, 20:25 ET — Market closed.

  • IonQ shares were last up about 0.2% at $45.31 after the close, after trading between $45.10 and $47.40.
  • The company said it finalized an agreement to deliver a 100-qubit Tempo quantum system to South Korea’s KISTI.
  • Quantum computing stocks have swung sharply into year-end amid profit-taking and thin holiday liquidity.

IonQ Inc shares were last up about 0.2% at $45.31 after U.S. markets closed on Tuesday, as investors weighed a newly detailed system delivery agreement in South Korea. More than 13.5 million shares changed hands and the stock traded between $45.10 and $47.40.

The agreement lands at a sensitive moment for the quantum computing trade. Investors have chased commercialization milestones — and punished perceived slippage — because most companies in the space are still early in converting research wins into durable revenue.

Quantum “pure plays” have been volatile into year-end, with profit-taking and lower institutional participation amplifying moves, Investors.com reported. The outlet said D-Wave Quantum has led gains in 2025, while IonQ and Rigetti Computing also rose, even as the group remained well below its highs and faced competition from larger tech firms. Investors.com

IonQ said late Monday it finalized an agreement to deliver a 100-qubit Tempo quantum system to South Korea’s Korea Institute of Science and Technology Information (KISTI), to be integrated with KISTI-6 “HANGANG,” which the company called the nation’s largest high-performance computing cluster. The platform will be available through a secure private cloud, with KISTI leading the platform’s development and operation and Megazone Cloud named as a project partner. “This is a defining moment for both IonQ and South Korea,” Chief Executive Niccolo de Masi said; the company did not disclose financial terms. IonQ Investors

A qubit is the basic unit of information in a quantum computer, which relies on quantum mechanics to tackle certain calculations that can overwhelm classical machines. High-performance computing, or HPC, refers to the supercomputer clusters used for large-scale research workloads.

For IonQ, the South Korea deployment keeps attention on execution — not just benchmarks. Investors typically want clearer line-of-sight on delivery timelines and whether hardware placements translate into recurring usage and follow-on orders.

Tuesday’s price action also showed traders still treating IonQ as a high-beta proxy for sentiment in the quantum theme. Even modest headlines can move the stock when volumes thin out late in the year.

The $45 area is now in focus after Tuesday’s low near $45.10, while the $47 zone marks a near-term hurdle after the stock topped out around $47.40 in the session. A break in either direction can draw momentum flows as market makers adjust positions around year-end.

Before the next session on Wednesday, traders will be watching whether IonQ holds that $45 support and whether buyers can push it back through the mid-$47 area. Small-cap growth names can see exaggerated swings around the turn of the year as funds rebalance.

On the company calendar, Zacks’ earnings calendar lists IonQ’s next quarterly report date as February 25, 2026, though companies can change schedules.

That report is expected to refocus investors on bookings, delivery timing for systems like Tempo, and the pace of spending needed to fund IonQ’s roadmap. Until then, the stock is likely to trade on system-delivery headlines and broader risk appetite in speculative tech.

Stock Market Today

  • CyberTech Systems Earnings Raise Cash Flow Concerns Amid Market Stability
    May 20, 2026, 8:56 PM EDT. CyberTech Systems and Software Limited (NSE:CYBERTECH) posted earnings that met market expectations but revealed an accrual ratio of 0.53, indicating weaker free cash flow relative to profit. This financial metric, which measures non-cash earnings, signals potential challenges for upcoming profits as free cash flow of ₹76 million lagged behind reported profit of ₹304.3 million for the year ending March 2026. Despite a 28% annual growth in earnings per share (EPS) over three years, the decline in cash conversion may raise investor caution. The company's accrual ratio improved last year, suggesting the current shortfall could be temporary, but shareholders are advised to monitor cash flow trends closely against profitability for a clearer outlook.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Newmont stock today: NEM ends higher as gold rebounds after sharp year-end swings
Previous Story

Newmont stock today: NEM ends higher as gold rebounds after sharp year-end swings

Circle (CRCL) stock slips into year-end close as Fed minutes keep rate bets in focus
Next Story

Circle (CRCL) stock slips into year-end close as Fed minutes keep rate bets in focus

Go toTop